We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

e-Therapeutics plc (ETX) Ordinary 0.1p

Sell:16.55p Buy:17.95p 0 Change: 0.50p (2.82%)
Market closed Prices as at close on 30 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:16.55p
Buy:17.95p
Change: 0.50p (2.82%)
Market closed Prices as at close on 30 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:16.55p
Buy:17.95p
Change: 0.50p (2.82%)
Market closed Prices as at close on 30 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

e-Therapeutics Plc provides computer-based drug discovery platform. The Company's platform is a combination of databases and a suite of computational tools that employ network analysis, data mining, machine learning, artificial intelligence (Al) and optimization. Its in silico platform serves as a laboratory, which enables it to computationally test potential therapeutic interventions. Its network-driven drug discovery (NDD) technology performs computational phenotypic screens to identify efficacious drugs. Its genome-associated interactions networks (GAINs) technology interprets genomic data in the context of the biological networks, in which the genes function. Its ribonucleic acid (RNA) Interference, (RNAi) platform is in development to complement its computational toolset. The Company identifies new therapeutic approaches to modulate a specific mechanism involved in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic indications through Galapagos NV (Galapagos).

Contact details

Address:
17 Blenheim Office Park
WITNEY
OX29 8LN
United Kingdom
Telephone:
+44 (01993) 880000
Website:
https://www.etherapeutics.co.uk/

Important dates

Future events
AGM 19 July 2022 19/07/22
Past events
Annual report 17 May 2022 17/05/22
Final results 04 May 2022 04/05/22
Interim results 26 October 2021 26/10/21

General stock information

EPIC:
ETX
ISIN:
GB00B2823H99
Market cap:
£87.48 million
Shares in issue:
514.57 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Ali Mortazavi
    Chief Executive Officer, Executive Director
  • Michael Bretherton
    Interim Chief Financial Officer, Non-Executive Director
  • Stephanie Maley
    Chief People Officer
  • Jonny Wray
    Chief Technology Officer
  • Alan Whitmore
    Chief Scientific Officer
  • Alison Gallafent
    Chief Intellectual Property Officer
  • Laura Roca-alonso
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.